Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]
Learn about PRP therapy, PRF, Intradermal Synthesized Mesotherapy (ISM), Transepidermal Delivery (TED) infusion therapy, medications, and lifestyle changes for hair regrowth
Our results also raise the question of what aspect(s) of ER functional capacity are altered by TCA cycle activity and glutathione redox
Research positions them as tools for metabolic exploration, with FDA approval based on trials involving thousands of participants